Related Experiment Video
Updated: Jun 19, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients
Tania Claeys1, Maria Van Dyck, Rita Van Damme-Lombaerts
1Department of Paediatric Medicine, University Hospital Leuven, Herestraat 49, Louvain, 3000 Vlaams-Brabant, Belgium. Tania.Claeys@uz.kuleuven.ac.be
Insights
Tacrolimus trough levels are unreliable for estimating drug exposure in pediatric kidney transplant patients. Limited sampling strategies, particularly three-point assessments, accurately predict tacrolimus exposure, supporting abbreviated monitoring.
Area of Science:
- Pharmacology
- Nephrology
- Transplantation
Background:
- Tacrolimus (Tac) has a narrow therapeutic index and variable pharmacokinetics.
- Monitoring Tac exposure is crucial but limited data exist for pediatric renal transplant recipients, especially regarding limited sampling strategies.
Purpose of the Study:
- To investigate the correlation between Tac trough level (TL) and the 0-12 h area under the curve (AUC).
- To evaluate the utility of abbreviated AUC monitoring in pediatric renal transplant recipients.
Main Methods:
- Evaluated 12-hour pharmacokinetic (PK) profiles in 27 children at least 1 year post-transplantation.
- Assessed the correlation between Tac trough levels and 0-12 h AUC.
- Determined the predictive value of various time points and limited sampling strategies for AUC estimation.
Main Results:
- Significant discrepancy observed between Tac TLs and 0-12 h AUC (r=0.60).
- Single time points C(4) and C(6) showed strong correlation with AUC (r=0.93 and r=0.92, respectively).
- Two- or three-point sampling strategies accurately estimated 0-12 h AUC, with three points being more time-point independent.
Conclusions:
- Tac TL is not a reliable indicator of drug exposure in stable pediatric renal transplant recipients on maintenance Tac therapy.
- Abbreviated AUC monitoring, especially using three time points, provides reliable drug exposure predictions.
- Suggested target 0-12 h AUC values: ~150 ng x h/ml at 1 year post-transplant and ~100 ng x h/ml in subsequent years, requiring further establishment based on time post-transplant.
Abstract:
Because tacrolimus (Tac) has a narrow therapeutic index and highly inter- and intra-individual variable pharmacokinetic (PK) characteristics, monitoring of drug exposure is recommended, but limited data are available on the kinetics of Tac in paediatric renal transplant recipients, especially of limited sampling strategies. To investigate the correlation between Tac trough level (TL) and the 0-12 h area under the curve (AUC), and the value of abbreviated AUC monitoring, we evaluated 12 h PK profiles in 27 children at least 1 year after transplantation. There was a significant discrepancy between Tac TLs and 0-12 h AUC (r = 0.60). Every time point, different from C(0), gave a better prediction for the drug exposure, with C(4) and C(6) as best predictors (r = 0.93 and r = 0.92, respectively). The 0-12 h AUC was estimated with great precision by the use of a two- or three-point sampling strategy, and the latter is more time-point independent. In paediatric renal transplant recipients on Tac maintenance therapy, whose condition is stable, Tac TL is not a reliable tool for the estimation of drug exposure. Abbreviated monitoring, especially at three points in time, give reliable predictions of the complete 0-12 h AUC. We suggest a 0-12 h AUC of around 150 ng x h/ml for stable paediatric renal transplant recipients 1 year after transplantation and around 100 ng x h/ml in the following years. Target AUC values should be further established for paediatric transplant recipients according to the time after transplantation.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Dosage Regimens: Partial Pharmacokinetic Parameters
